Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand-1 (PD-L1) ≥ 50% advanced non-small cell lung cancer (NSCLC). We reviewed the real-world outcomes of patients who received pembro-chemo versus pembro only. METHODS: This Australian-based retrospective cohort study used data from patients with advanced NSCLC PD-L1 ≥ 50%, diagnosed between January 2016 and July 2021 and had received first-line pembro-chemo or pembro only. Patients with an EGFR/ALK/ROS1 sensitizing mutation were excluded. Cox proportional-hazards model and Kaplan-Meier methods were used to estimate OS and progression-free survival (PFS). RESULTS: Of 111 eligible patients, 25 received pembro-chemo and 86 received pembro only. After a median follow-up of 15.7 months, median (95% CI) OS was not reached in the pembro-chemo group versus 15.6 (9.5-21.7) months in the pembro-only group (HR 0.57, 95% CI 0.28-1.16, p = 0.12). Median PFS was 12.4 (6.5-18.3) versus 9.5 (6.3-12.6) months in pembro-chemo versus pembro-only groups, respectively (HR 0.62, 95% CI 0.32-1.18, p = 0.18). Objective response rate (ORR) was higher in the pembro-chemo group (60% vs. 30.3%). There were more hospitalizations in the pembro-chemo group versus pembro-only group, 28% versus 18.6%, but immune-related adverse events were similar (32% vs. 32.6%). CONCLUSION: In patients with PD-L1 ≥ 50% advanced NSCLC, addition of chemo to first-line pembro yielded a higher ORR but no additional benefit in PFS or OS, supporting a shared-decision approach. However, higher rates of hospitalizations seen in the pembro-chemo group should warrant caution in use.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy
- Date Crossref
- 17/06/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Camden and Campbelltown Hospitals pays non établi dans la noticeÉtablissement de santé
-
Western Sydney University pays non établi dans la noticeUniversité ou école supérieure
-
Liverpool Hospital pays non établi dans la noticeÉtablissement de santé
-
The University of Sydney pays non établi dans la noticeUniversité ou école supérieure
-
Cooperative Trials Group for Neuro-Oncology pays non établi dans la noticeInstitution
-
National Health and Medical Research Council pays non établi dans la noticeOrganisme public
-
Campbelltown Hospital Campbelltown NSW Australia Macarthur Cancer Therapy Centre pays non établi dans la noticeÉtablissement de santé
Camden and Campbelltown Hospitals, Western Sydney University et Liverpool Hospital, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.